Wan Yu Kang

Wanyukang is a Beijing-based biotechnology company specializing in the development of innovative immune cell therapies, with a primary focus on Natural Killer (NK) cell and CAR-NK cell technologies. The company leverages its proprietary platforms to engineer off-the-shelf cell products derived from induced pluripotent stem cells (iPSCs) aimed at treating various hematological malignancies and solid tumors. Wanyukang's research emphasizes improving the persistence and efficacy of NK cells within the tumor microenvironment through advanced gene editing and synthetic biology. By utilizing standardized expansion techniques and universal cell sources, the company aims to provide more accessible and cost-effective immunotherapy options for cancer patients.